SCHEMBL3837962

SCHEMBL3837962

FC(F)(F)c1ccc(-c2nc3c(s2)CNCC3)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 2/20 0.47
TLR7 Q9NYK1 2/20 0.47
TLR8 Q9NR97 1/20 0.47
PDCD1 Q15116 8/20 0.46
CD274 Q9NZQ7 8/20 0.46
HTR2C P28335 3/20 0.43
HTR2B P41595 3/20 0.43
HTR2A P28223 2/20 0.43
MCHR1 Q99705 1/20 0.40
HDAC2 Q92769 1/20 0.39
FGFR3 P22607 1/20 0.39
KDR P35968 1/20 0.39
DPP4 P27487 1/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP9 Q86TI2 1/20 0.39
DPP7 Q9UHL4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1261819 0.89 PDCD1 (0.49) TLR9TLR7TLR8PDCD1CD274
Hydrochloric Acid SCHEMBL1262005 0.88 PDCD1 (0.48) TLR9TLR7TLR8PDCD1CD274
SCHEMBL15933626 0.84 ASIC3 (0.51) TLR9TLR7TLR8PDCD1CD274
SCHEMBL3156931 0.84 PDCD1 (0.54) TLR9TLR7TLR8PDCD1CD274
Hydrochloric Acid SCHEMBL30785571 0.83 PDCD1 (0.53) TLR9TLR7TLR8PDCD1CD274
SCHEMBL12340037 0.82 PDCD1 (0.52) TLR9TLR7TLR8PDCD1CD274
SCHEMBL15933482 0.81 PDCD1 (0.54) TLR9TLR7TLR8PDCD1CD274
SCHEMBL15933483 0.81 PDCD1 (0.48) TLR9TLR7TLR8PDCD1CD274
SCHEMBL15933625 0.81 PDCD1 (0.48) TLR9TLR7TLR8PDCD1CD274
SCHEMBL327547 0.81 PDCD1 (0.48) TLR9TLR7TLR8PDCD1CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014117318-A1 NOVEL TRIAZOLE ANTIFUNGAL COMPOUNDS, AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD, AND APPLICATION THEREOF 中国科学院上海药物研究所 (CN) 2014-08-07 WO disclosed
EP-1979360-B1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2009-10-14 EP disclosed
US-20090088368-A1 COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS IRM LLC (BM) 2009-04-02 US disclosed
US-20090088368-A1 COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS IRM LLC (BM) 2009-04-02 US disclosed
US-20090088368-A1 COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS IRM LLC (BM) 2009-04-02 US disclosed
EP-1979360-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2008-10-15 EP disclosed
US-7265128-B2 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK & CO., INC. (US) 2007-09-04 US disclosed
US-7265128-B2 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK & CO., INC. (US) 2007-09-04 US disclosed
US-7265128-B2 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK & CO., INC. (US) 2007-09-04 US disclosed
WO-2007089667-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2007-08-09 WO disclosed
WO-2007089667-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2007-08-09 WO disclosed
US-20060069116-A1 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK SHARP & DOHME LLC 2006-03-30 US disclosed
WO-2004064778-A2 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO. INC. (US) 2004-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069116-A1 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes DPP4, DPP3, DPP7 TLR9 3211/4885TLR7 3742/4885TLR8 3083/4885
US-20090088368-A1 COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS PPARG, PPARA, PPARD TLR9 1240/4885TLR7 1988/4885TLR8 1057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.